journal
MENU ▼
Read by QxMD icon Read
search

British Journal of Haematology

journal
https://www.readbyqxmd.com/read/30239982/patient-and-physician-preferences-for-first-line-treatment-of-classical-hodgkin-lymphoma-in-germany-france-and-the-united-kingdom
#1
Paul J Bröckelmann, Suzanne McMullen, J Ben Wilson, Kerstin Mueller, Sarah Goring, Aspasia Stamatoullas, Erin Zagadailov, Ashish Gautam, Dirk Huebner, Mehul Dalal, Tim Illidge
First-line treatments for classical Hodgkin lymphoma (HL) include ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) and BEACOPPescalated (escalated dose bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone). To further improve overall outcomes, positron emission tomography-driven strategies and ABVD or BEACOPP variants incorporating the antibody-drug conjugate brentuximab vedotin (BV) or anti-PD1 antibodies are under investigation in advanced-stage patients. The present study aimed to elicit preferences for attributes associated with ABVD, BEACOPPescalated and BV-AVD (BV, adriamycin, vinblastine and dacarbazine) among patients and physicians...
September 21, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/30216417/disease-site-as-a-prognostic-factor-for-mycosis-fungoides-an-analysis-of-2428-cases-from-the-us-national-cancer-database
#2
LETTER
Chang Su, Rui Tang, Harrison X Bai, Michael Girardi, Giorgos Karakousis, Paul J Zhang, Rong Xiao, Guiying Zhang
No abstract text is available yet for this article.
September 14, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/30203841/avatrombopag-an-oral-thrombopoietin-receptor-agonist-results-of-two-double-blind-dose-rising-placebo-controlled-phase-1-studies
#3
David J Kuter, Lee F Allen
Avatrombopag is an oral thrombopoietin receptor agonist that has been recently approved for treating thrombocytopenia in chronic liver disease patients needing invasive procedures. Clinical trials supporting this new treatment were guided by two double-blind, dose-rising, placebo-controlled Phase 1 studies in healthy adults reported here that assessed safety, tolerability and pharmacokinetic profile of avatrombopag, and its effect on platelet counts. Subjects were randomised (2:1) in the single-dose study (N = 63) to avatrombopag (1, 3, 10, 20, 50, 75 and 100 mg) or placebo, and in the multiple-dose study (N = 29) to avatrombopag (3, 10 and 20 mg) or placebo daily for 14 days...
September 11, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/30203839/predictors-of-response-to-anti-il6-monoclonal-antibody-therapy-siltuximab-in-idiopathic-multicentric-castleman-disease-secondary-analyses-of-phase-ii-clinical-trial-data
#4
Deanna E Morra, Sheila K Pierson, Dustin Shilling, Sepideh Nemat, Carlos Appiani, Mary Guilfoyle, Craig Tendler, Frits van Rhee, David C Fajgenbaum
Siltuximab is the only US Food and Drug Administration-approved treatment for idiopathic multicentric Castleman disease (iMCD), a rare haematological disorder associated with substantial morbidity and mortality. Although siltuximab induces a response in a significant proportion of iMCD patients via interleukin 6 (IL6) neutralization, it is not universally effective. To develop a predictive model of response, we performed an in-depth analysis of 38 baseline laboratory parameters in iMCD patients from the phase II siltuximab trial who met criteria for treatment response or treatment failure...
September 11, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/30203837/extreme-hyperferritinaemia-soluble-interleukin-2-receptor-and-haemophagocytic-lymphohistiocytosis
#5
LETTER
Luke Y C Chen, Anna Hayden, Andre Mattman
No abstract text is available yet for this article.
September 11, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/30203835/an-unexpected-diagnosis-angiosarcoma-with-bone-marrow-involvement-mimicking-a-myeloproliferative-neoplasm
#6
Wei Xie, Pei Lin, Sergej Konoplev
No abstract text is available yet for this article.
September 11, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/30203833/clinical-value-of-automated-fibrin-generation-markers-in-patients-with-septic-shock-a-sepsicoag-ancillary-study
#7
Jean-Christophe Gris, Eva Cochery-Nouvellon, Sylvie Bouvier, Samir Jaber, Jacques Albanese, Jean-Michel Constantin, Jean-Christophe Orban, Jérôme Morel, Marc Leone, Pauline Deras, Loubna Elotmani, Géraldine Lavigne-Lissalde, Jean-Yves Lefrant
An ancillary analysis to the SepsiCoag multicentric prospective observational study on patients entering an intensive care unit with septic shock evaluated the prognostic potential of fibrin generation markers (FGMs) tested at inclusion in the study, on survival at day 30. After centralization of samples, three automated FGMs were compared: D-dimers (DDi), fibrin/fibrinogen degradation products (FDP) and fibrin monomers (FM). FM was the single FGM that was significantly higher in non-surviving patients, area under the receiver-operator characteristic curve (AUCROC ): 0·617, P < 0·0001...
September 11, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/30203832/a-phase-1-2-open-label-dose-escalation-study-of-midostaurin-in-children-with-relapsed-or-refractory-acute-leukaemia
#8
LETTER
C Michel Zwaan, Stefan Söderhäll, Benoit Brethon, Matteo Luciani, Carmelo Rizzari, Ronald W Stam, Emmanuelle Besse, Catherine Dutreix, Franca Fagioli, Phoenix A Ho, Carlo Dufour, Rob Pieters
No abstract text is available yet for this article.
September 11, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/30203489/safety-and-efficacy-of-vismodegib-in-relapsed-refractory-acute-myeloid-leukaemia-results-of-a-phase-ib-trial
#9
LETTER
Dale Bixby, Richard Noppeney, Tara L Lin, Jorge Cortes, Jürgen Krauter, Karen Yee, Bruno C Medeiros, Alwin Krämer, Sarit Assouline, Walter Fiedler, Natalie Dimier, Brian P Simmons, Todd Riehl, Dawn Colburn
No abstract text is available yet for this article.
September 11, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/30203425/study-of-gene-polymorphisms-as-predictors-of-treatment-efficacy-and-toxicity-in-patients-with-indolent-non-hodgkin-lymphomas-and-mantle-cell-lymphoma-receiving-bendamustine-and-rituximab
#10
Emanuele Cencini, Anna Sicuranza, Alberto Fabbri, Ilaria Ferrigno, Luigi Rigacci, Maria C Cox, Donatella Raspadori, Monica Bocchia
Bendamustine is used in combination with rituximab (BR) to treat indolent non-Hodgkin lymphomas (iNHL) and mantle cell lymphoma (MCL). The variability in treatment efficacy and toxicity could be related to single nucleotide polymorphisms (SNPs) in immune response genes. We would like to show a correlation between SNPs and treatment outcome in iNHL and MCL patients receiving BR. We investigated some SNPs that had already been associated with NHL outcome. Samples were genotyped for the IL2 (rs2069762), IL10 (rs1800890, rs10494879), VEGFA (rs3025039), IL8 (rs4073), CFH (rs1065489) and MTHFR (rs1801131) SNPs by allelic discrimination assays...
September 11, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/30203413/myasthenia-gravis-unmasked-by-imatinib
#11
Chirag R Kopp, Aditya Jandial, Kundan Mishra, Rajeev Sandal, Pankaj Malhotra
No abstract text is available yet for this article.
September 10, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/30198572/novel-mutations-in-spta1-and-sptb-identified-by-whole-exome-sequencing-in-eight-thai-families-with-hereditary-pyropoikilocytosis-presenting-with-severe-fetal-and-neonatal-anaemia
#12
LETTER
Chupong Ittiwut, Rungrote Natesirinilkul, Fuanglada Tongprasert, Lalita Sathitsamitphong, Chane Choed-Amphai, Kanda Fanhchaksai, Pimlak Charoenkwan, Kanya Suphapeetiporn, Vorasuk Shotelersuk
No abstract text is available yet for this article.
September 10, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/30198571/pulmonary-toxicity-in-paediatric-patients-with-relapsed-or-refractory-hodgkin-lymphoma-receiving-brentuximab-vedotin
#13
Kelly E Faulk, Jenna M Sopfe, Kristen Campbell, Deborah R Liptzin, Arthur K Liu, Anna R K Franklin, Carrye R Cost
Brentuximab vedotin (Bv) is becoming increasingly important in the treatment of Hodgkin lymphoma (HL), with improved outcomes and an overall favourable toxicity profile. However, Bv is associated with severe pulmonary toxicity when combined with bleomycin, suggesting that additive toxicity may be an important consideration. Furthermore, little has been published on tolerability in paediatric patients. We retrospectively evaluated the occurrence of pulmonary toxicity of Bv in 19 paediatric and young adult patients with relapsed or refractory HL...
September 10, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/30198570/whole-exome-sequencing-discloses-heterozygous-variants-in-the-dnajc21-and-efl1-genes-but-not-in-srp54-in-6-out-of-16-patients-with-shwachman-diamond-syndrome-carrying-biallelic-sbds-mutations
#14
LETTER
Jacopo Morini, Lucia Nacci, Gabriele Babini, Simone Cesaro, Roberto Valli, Andrea Ottolenghi, Elena Nicolis, Emily Pintani, Emanuela Maserati, Marco Cipolli, Cesare Danesino, Claudia Scotti, Antonella Minelli
No abstract text is available yet for this article.
September 10, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/30198569/the-mir-17-92-cluster-activates-mtorc1-in-mantle-cell-lymphoma-by-targeting-multiple-regulators-in-the-stk11-ampk-tsc-mtor-pathway
#15
LETTER
Chunsun Jiang, Chengfeng Bi, Xiaoxing Jiang, Tian Tian, Xin Huang, Cheng Wang, Mario R Fernandez, Javeed Iqbal, Wing C Chan, Timothy W McKeithan, Robert E Lewis, Kai Fu
No abstract text is available yet for this article.
September 10, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/30198568/cd13-expression-in-b-cell-malignancies-is-a-hallmark-of-plasmacytic-differentiation
#16
Anna Raimbault, Sigrid Machherndl-Spandl, Raphaël Itzykson, Sylvain Clauser, Nicolas Chapuis, Stéphanie Mathis, Jeroen Lauf, Anne-Sophie Alary, Barbara Burroni, Olivier Kosmider, Michaela Fontenay, Marie C Béné, Françoise Durrieu, Peter Bettelheim, Valérie Bardet
The diagnosis of Waldenström Macroglobulinaemia (WM)/lymphoplasmacytic lymphoma (LPL) remains one of exclusion because other B-cell lymphoproliferative disorders (B-LPD), such as marginal zone lymphoma (MZL), can fulfil similar criteria, including MYD88 L265P mutation. It has been suggested that expression of the myeloid marker CD13 (also termed ANPEP) is more frequent in LPL than in other B-LPD and has also been described on normal and malignant plasma cells. Here, CD13 expression was tested in a cohort of 1037 B-LPD patients from 3 centres by flow cytometry...
September 10, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/30198565/plasma-metabolomics-analysis-in-sickle-cell-disease-patients-with-albuminuria-an-exploratory-study
#17
LETTER
Laila Elsherif, Wimal Pathmasiri, Susan McRitchie, David R Archer, Kenneth I Ataga
No abstract text is available yet for this article.
September 10, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/30198552/diagnosis-of-pulmonary-embolism-should-we-wait-years
#18
EDITORIAL
Raza Alikhan, Heledd Roberts
No abstract text is available yet for this article.
September 10, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/30198551/lower-prevalence-of-subsegmental-pulmonary-embolism-after-application-of-the-years-diagnostic-algorithm
#19
Liselotte M van der Pol, Ingrid M Bistervels, Thijs E van Mens, Tom van der Hulle, Ludo F M Beenen, Paul L den Exter, Lucia J M Kroft, Albert T A Mairuhu, Saskia Middeldorp, Jaap M van Werkhoven, Marije Ten Wolde, Menno V Huisman, Frederikus A Klok
The rate of identified isolated subsegmental pulmonary embolism (ssPE) has doubled with advances in computed tomography pulmonary angiography (CTPA) technology, but its clinical relevance is debated. The YEARS diagnostic algorithm was shown to safely reduce the number of required CTPAs in the diagnostic management of PE. We hypothesized that the higher threshold for performing CTPA in YEARS was associated with a lower prevalence of ssPE compared to the conventional diagnostic algorithm. We compared 2291 consecutive patients with suspected PE managed according to YEARS to 3306 consecutive control patients managed according to the Wells score for the prevalence of isolated ssPE...
September 10, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/30198549/prognostic-factors-and-primary-treatment-for-waldenstr%C3%A3-m-macroglobulinemia-a-swedish-lymphoma-registry-study
#20
Lena Brandefors, Beatrice Melin, Jack Lindh, Kristina Lundqvist, Eva Kimby
We present a nationwide prospective Swedish registry-based study of Waldenström macroglobulinaemia (WM), that focuses on incidence and survival in relation to clinical prognostic factors and primary systemic therapies. A total of 1511 patients with WM and lymphoplasmocytic lymphoma (LPL) were registered in the Swedish Lymphoma Registry (SLR) between 1 January 2000 and 31 December 2014. The age-adjusted incidence of WM/LPL was 11·5 per million persons per year, three times higher than the reported incidence worldwide...
September 10, 2018: British Journal of Haematology
journal
journal
20057
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"